Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.49 |
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334044 | 0.91 | PDE4D (0.48) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL2339351 | 0.88 | IKBKB (0.40) | — | |
| SCHEMBL15006655 | 0.87 | PTGDR2 (0.49) | GPR119DNMT3ABRD3 | |
| SCHEMBL2331889 | 0.84 | EPHX2 (0.40) | — | |
| SCHEMBL2333744 | 0.82 | L3MBTL1 (0.49) | — | |
| SCHEMBL2334359 | 0.81 | SLC6A2 (0.41) | IDO1 | |
| SCHEMBL2336150 | 0.78 | PTGDR2 (0.48) | — | |
| SCHEMBL20576250 | 0.77 | PDE4B (0.52) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL15006641 | 0.76 | GPR119 (0.46) | GPR119DNMT3ABRD3 | |
| SCHEMBL23360225 | 0.76 | IDO1 (0.53) | PDE4DPDE4BPDE4APDE4CGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358677-B1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2358677-B1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8188090-B2 | Naphthylacetic acids | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188090-B2 | Naphthylacetic acids | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188090-B2 | Naphthylacetic acids | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2358677-A1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| WO-2010055006-A1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | PDE4D 1042/4885PDE4B 952/4885PDE4A 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.